Developer docs
API playgroundTry for free, no card

Search company profiles

IgGenix

Full company profile

uuid0000cay

Namestring
IgGenix
Legal namestring
IgGenix, Inc.
Websiteurl
iggenix.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

IgGenix, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered at Lilly Gateway Labs in South San Francisco, California. The company develops antibody therapeutics for IgE-mediated allergic diseases using its proprietary SEQ SIFTER™ platform—a single-cell RNA-sequencing-based discovery technology that captures extremely rare human B cells producing IgE antibodies directly from patient blood and re-engineers them into fully human, high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. IgGenix's lead product candidate is IGNX001, a first-in-class human IgG4 monoclonal antibody for peanut allergy that completed Phase 1 enrollment in September 2025. The broader pipeline targets additional food allergies (egg, fish, milk, sesame, shellfish, soy, tree nuts, wheat), environmental allergies (cat, dog, dust, mold, pollen), atopic dermatitis, and alpha-gal syndrome.

The company has raised approximately $75 million in venture capital across three funding rounds (Series A $10M in 2020, Series A1 $25M in 2021, Series B $40M in 2023) from investors including Khosla Ventures, Alexandria Venture Investments, Eli Lilly and Company, Prosperity Capital Management, Sean Parker, AllerFund, ShangBay Capital, Global Brain, and Parker Ventures. IgGenix operates an exclusive license from CZ Biohub SF, LLC to foundational patent No. 11,613,569 covering allergen-specific antibody generation methods. The business model is pharmaceutical therapeutic development: future revenue is expected to derive from commercialization of approved antibody products via traditional pharmaceutical channels (physician prescribing, specialty pharmacy distribution), though no products are yet approved and no pricing has been disclosed. Customer segments target both pediatric and adult allergy patients across food and environmental allergies, with a horizontal segmentation approach addressing multiple allergen categories.

Short descriptiontext

IgGenix is a clinical-stage biotechnology company developing first-in-class human IgG4 monoclonal antibody therapeutics for IgE-mediated allergic diseases, using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform to discover allergen-blocking antibodies from allergic patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, monoclonal antibody discovery, allergy immunotherapy, clinical-stage biotechnology, biologics development
Industry2 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
Product category
Allergy Biologics / Antibody Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Drug Development and Commercialization
TypeOne Time License
Description

IgGenix is developing antibody therapeutics for allergic diseases. As a clinical-stage biotechnology company, revenue will be generated through the commercialization of approved therapeutic products, initially targeting peanut allergy with IGNX001, and subsequently expanding to other food and environmental allergies.

iggenix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IgGenix is a clinical-stage biotechnology company developing antibody therapeutics for allergic diseases. Using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform, the company isolates rare human IgE-producing B cells and re-engineers them into high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and is currently in Phase 1 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 1 ACCELERATE Peanut trial enrolled approximately 24 participants with peanut allergy, with enrollment completed in September 2025
+4 more records
Product overview1 text field

IgGenix is a clinical-stage antibody discovery and development company with a pipeline focused on IgE-mediated allergic diseases. The company's core technology is the SEQ SIFTER™ platform, a single-cell RNA-sequencing-based discovery platform that isolates and re-engineers human IgE antibodies into therapeutic IgG antibodies. The lead product is IGNX001, a first-in-class IgG4 monoclonal antibody therapeutic for peanut allergy currently completing Phase 1 clinical trials (ACCELERATE Peanut Study). The pipeline includes additional food allergy programs, an atopic dermatitis program, and research into Alpha-gal Syndrome. The company targets both pediatric and adult patients across food and environmental allergies including peanut, egg, fish, milk, sesame, shellfish, soy, tree nuts, wheat, cat, dog, dust, mold, and pollen allergens.

Product and service5 records
1IGNX001
CategoryTherapeutic Biologic
Description

A first-in-class, high-affinity, human IgG4 monoclonal antibody therapeutic designed to prevent allergic reactions caused by accidental peanut allergen exposure by blocking the binding of peanut allergens to IgE antibodies. Indicated for adults and adolescents (ages 15-18) with peanut allergy.

2Allergy Program #2
CategoryPipeline Therapeutic Program
Description

Second food allergy development program in IgGenix's pipeline, currently at 50% completion (Lead Selection stage), targeting an undisclosed allergen.

3Allergy Program #3
CategoryPipeline Therapeutic Program
Description

Third food allergy development program in IgGenix's pipeline, currently at 25% completion (Lead Selection stage), targeting an undisclosed allergen.

4Atopic Dermatitis Program
CategoryPipeline Therapeutic Program
Description

Development program targeting atopic dermatitis and other atopic/autoimmune conditions where IgE plays a role, currently at 12% completion in discovery stage.

5SEQ SIFTER™ Discovery Platform
CategoryAntibody Discovery Platform
Description

Proprietary single-cell RNA-sequencing-based antibody discovery platform that captures extremely rare human B cells producing IgE antibodies directly from human blood, then isolates and re-engineers them into fully human, high-affinity, allergen-specific IgG4 antibodies designed to block and prevent the allergic cascade. Foundation of IgGenix's pipeline.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-04-04
Description

Patent No. 11,613,569 is exclusively licensed from CZ Biohub SF, LLC and serves as the foundation for IgGenix's proprietary SEQ SIFTER™ platform. This exclusive license enables IgGenix to commercialize technology developed from foundational research at Stanford University.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-26
Description

IgGenix moved its headquarters to Lilly Gateway Labs in South San Francisco, a shared innovation laboratory operated by Eli Lilly and Company. This collaboration offers potential access to Lilly scientists, team members and executives, as well as scientific and functional expertise. Companies may collaborate with Lilly on projects of mutual interest, participate in shared learning forums, and potentially receive financial investment from Lilly and their venture network.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Prota Therapeutics is an early-stage food allergy immunotherapy company developing peanut oral immunotherapy approaches. It is a stage-comparable peer in food allergy therapeutics.

TypeEmerging player
Description

Mabylon AG is a Swiss biotech developing human antibody therapeutics for allergies and inflammatory diseases. It is a peer to IgGenix in therapeutic antibody approaches to allergy.

3Alladapt Immunotherapeutics
TypeDirect peer
Description

Alladapt is a clinical-stage food allergy immunotherapy company developing a multi-food oral immunotherapy for peanut plus other allergens. It targets the same patient population as IgGenix with a similar stage of development.

TypeDirect peer
Description

Allergy Therapeutics is a commercial-stage allergy immunotherapy company developing both subcutaneous and novel short-course allergy immunotherapies across multiple allergens. It is a peer in the broader allergy immunotherapy category.

TypeBroad incumbent
Description

Sanofi is Regeneron's Dupixent partner and a major immunology/inflammation pharma incumbent with broad allergy, asthma, and atopic dermatitis franchises. It is a broad incumbent and a potential strategic acquirer of IgGenix.

TypeBroad incumbent
Description

Regeneron co-developed Dupixent (dupilumab), a leading immunology biologic approved across multiple allergic and atopic indications including atopic dermatitis. It is a broad incumbent whose franchises overlap with IgGenix's eventual commercial space.

TypeEmerging player
Description

AnaptysBio is a clinical-stage antibody company developing inflammatory and immunology therapeutics. It shares IgGenix's therapeutic antibody development approach and inflammation/immunology focus, though targeting different indications.

TypeDirect peer
Description

DBV Technologies is developing Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It competes head-to-head in the peanut allergy therapeutic space where IgGenix's IGNX001 is positioned.

TypeDirect peer
Description

Aimmune Therapeutics developed Palforzia, the first FDA-approved oral immunotherapy (OIT) for peanut allergy, now owned by Nestlé Health Science. It is the most direct competitor in peanut allergy therapeutics and a benchmark for IgGenix's lead indication.

TypeEmerging player
Description

Arcutis Biotherapeutics is a commercial-stage company focused on immuno-dermatology, including atopic dermatitis, overlapping with IgGenix's atopic dermatitis program indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IgGenix

Allergy Biologics / Antibody Therapeuticsiggenix.com

IgGenix is a clinical-stage biotechnology company developing first-in-class human IgG4 monoclonal antibody therapeutics for IgE-mediated allergic diseases, using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform to discover allergen-blocking antibodies from allergic patients.

What IgGenix does

IgGenix, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered at Lilly Gateway Labs in South San Francisco, California. The company develops antibody therapeutics for IgE-mediated allergic diseases using its proprietary SEQ SIFTER™ platform—a single-cell RNA-sequencing-based discovery technology that captures extremely rare human B cells producing IgE antibodies directly from patient blood and re-engineers them into fully human, high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. IgGenix's lead product candidate is IGNX001, a first-in-class human IgG4 monoclonal antibody for peanut allergy that completed Phase 1 enrollment in September 2025. The broader pipeline targets additional food allergies (egg, fish, milk, sesame, shellfish, soy, tree nuts, wheat), environmental allergies (cat, dog, dust, mold, pollen), atopic dermatitis, and alpha-gal syndrome.

The company has raised approximately $75 million in venture capital across three funding rounds (Series A $10M in 2020, Series A1 $25M in 2021, Series B $40M in 2023) from investors including Khosla Ventures, Alexandria Venture Investments, Eli Lilly and Company, Prosperity Capital Management, Sean Parker, AllerFund, ShangBay Capital, Global Brain, and Parker Ventures. IgGenix operates an exclusive license from CZ Biohub SF, LLC to foundational patent No. 11,613,569 covering allergen-specific antibody generation methods. The business model is pharmaceutical therapeutic development: future revenue is expected to derive from commercialization of approved antibody products via traditional pharmaceutical channels (physician prescribing, specialty pharmacy distribution), though no products are yet approved and no pricing has been disclosed. Customer segments target both pediatric and adult allergy patients across food and environmental allergies, with a horizontal segmentation approach addressing multiple allergen categories.

IgGenix firmographics

Firmographics
Name
IgGenix
Legal name
IgGenix, Inc.
Website
https://iggenix.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
IgGenix is a clinical-stage biotechnology company developing first-in-class human IgG4 monoclonal antibody therapeutics for IgE-mediated allergic diseases, using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform to discover allergen-blocking antibodies from allergic patients.
Ownership category
akta.pro rank

IgGenix industry classification

Industry
Product category
Allergy Biologics / Antibody Therapeutics
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Antibody therapeutics
  • Monoclonal antibody discovery
  • Allergy immunotherapy
  • Clinical-stage biotechnology
  • Biologics development

Where IgGenix is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IgGenix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutic Drug Development and Commercialization: IgGenix is developing antibody therapeutics for allergic diseases. As a clinical-stage biotechnology company, revenue will be generated through the commercialization of approved therapeutic products, initially targeting peanut allergy with IGNX001, and subsequently expanding to other food and environmental allergies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

IgGenix product offering

Product offering

Core offering

IgGenix is a clinical-stage biotechnology company developing antibody therapeutics for allergic diseases. Using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform, the company isolates rare human IgE-producing B cells and re-engineers them into high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and is currently in Phase 1 clinical trials.

Product overview

IgGenix is a clinical-stage antibody discovery and development company with a pipeline focused on IgE-mediated allergic diseases. The company's core technology is the SEQ SIFTER™ platform, a single-cell RNA-sequencing-based discovery platform that isolates and re-engineers human IgE antibodies into therapeutic IgG antibodies. The lead product is IGNX001, a first-in-class IgG4 monoclonal antibody therapeutic for peanut allergy currently completing Phase 1 clinical trials (ACCELERATE Peanut Study). The pipeline includes additional food allergy programs, an atopic dermatitis program, and research into Alpha-gal Syndrome. The company targets both pediatric and adult patients across food and environmental allergies including peanut, egg, fish, milk, sesame, shellfish, soy, tree nuts, wheat, cat, dog, dust, mold, and pollen allergens.

Differentiator

Problem solved

Functional benefit

Products and services

  • IGNX001 A first-in-class, high-affinity, human IgG4 monoclonal antibody therapeutic designed to prevent allergic reactions caused by accidental peanut allergen exposure by blocking the binding of peanut allergens to IgE antibodies. Indicated for adults and adolescents (ages 15-18) with peanut allergy.
  • Allergy Program #2 Second food allergy development program in IgGenix's pipeline, currently at 50% completion (Lead Selection stage), targeting an undisclosed allergen.
  • Allergy Program #3 Third food allergy development program in IgGenix's pipeline, currently at 25% completion (Lead Selection stage), targeting an undisclosed allergen.
  • Atopic Dermatitis Program Development program targeting atopic dermatitis and other atopic/autoimmune conditions where IgE plays a role, currently at 12% completion in discovery stage.
  • SEQ SIFTER™ Discovery Platform Proprietary single-cell RNA-sequencing-based antibody discovery platform that captures extremely rare human B cells producing IgE antibodies directly from human blood, then isolates and re-engineers them into fully human, high-affinity, allergen-specific IgG4 antibodies designed to block and prevent the allergic cascade. Foundation of IgGenix's pipeline.

Quantifiable outcome

  • Phase 1 ACCELERATE Peanut trial enrolled approximately 24 participants with peanut allergy, with enrollment completed in September 2025
  • +4 more outcomes

Companies that use IgGenix

Customer profile

Segments4 records

Ideal customer profiles2 records

IgGenix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IgGenix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CZ Biohub SF, LLCcoreTechnology or Integration · 4 April 2023Patent No. 11,613,569 is exclusively licensed from CZ Biohub SF, LLC and serves as the foundation for IgGenix's proprietary SEQ SIFTER™ platform. This exclusive license enables IgGenix to commercialize technology developed from foundational research at Stanford University.
  • Lilly Gateway LabscoreStrategic or Co-development Partner · 26 April 2022IgGenix moved its headquarters to Lilly Gateway Labs in South San Francisco, a shared innovation laboratory operated by Eli Lilly and Company. This collaboration offers potential access to Lilly scientists, team members and executives, as well as scientific and functional expertise. Companies may collaborate with Lilly on projects of mutual interest, participate in shared learning forums, and potentially receive financial investment from Lilly and their venture network.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

IgGenix competitors and assessment

Company assessment

Emerging players

  • Prota Therapeutics: Prota Therapeutics is an early-stage food allergy immunotherapy company developing peanut oral immunotherapy approaches. It is a stage-comparable peer in food allergy therapeutics.
  • Mabylon AG: Mabylon AG is a Swiss biotech developing human antibody therapeutics for allergies and inflammatory diseases. It is a peer to IgGenix in therapeutic antibody approaches to allergy.
  • AnaptysBio: AnaptysBio is a clinical-stage antibody company developing inflammatory and immunology therapeutics. It shares IgGenix's therapeutic antibody development approach and inflammation/immunology focus, though targeting different indications.
  • Arcutis Biotherapeutics: Arcutis Biotherapeutics is a commercial-stage company focused on immuno-dermatology, including atopic dermatitis, overlapping with IgGenix's atopic dermatitis program indication.

Direct peers

  • Alladapt Immunotherapeutics: Alladapt is a clinical-stage food allergy immunotherapy company developing a multi-food oral immunotherapy for peanut plus other allergens. It targets the same patient population as IgGenix with a similar stage of development.
  • Allergy Therapeutics: Allergy Therapeutics is a commercial-stage allergy immunotherapy company developing both subcutaneous and novel short-course allergy immunotherapies across multiple allergens. It is a peer in the broader allergy immunotherapy category.
  • DBV Technologies: DBV Technologies is developing Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It competes head-to-head in the peanut allergy therapeutic space where IgGenix's IGNX001 is positioned.
  • Aimmune Therapeutics: Aimmune Therapeutics developed Palforzia, the first FDA-approved oral immunotherapy (OIT) for peanut allergy, now owned by Nestlé Health Science. It is the most direct competitor in peanut allergy therapeutics and a benchmark for IgGenix's lead indication.

Broad incumbents

  • Sanofi: Sanofi is Regeneron's Dupixent partner and a major immunology/inflammation pharma incumbent with broad allergy, asthma, and atopic dermatitis franchises. It is a broad incumbent and a potential strategic acquirer of IgGenix.
  • Regeneron Pharmaceuticals: Regeneron co-developed Dupixent (dupilumab), a leading immunology biologic approved across multiple allergic and atopic indications including atopic dermatitis. It is a broad incumbent whose franchises overlap with IgGenix's eventual commercial space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

IgGenix social profiles

Digital presence

IgGenix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IgGenix leadership team

Management profile

Number of profiles

Profiles12 records

IgGenix funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IgGenix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IgGenix

What does IgGenix do?

IgGenix is a clinical-stage biotechnology company developing antibody therapeutics for allergic diseases. Using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform, the company isolates rare human IgE-producing B cells and re-engineers them into high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and is currently in Phase 1 clinical trials.

Is IgGenix a public or private company?

IgGenix is a private company. It is classified as venture growth investor backed and is currently operating.

When was IgGenix founded?

IgGenix was founded in 2019. It employs 1 to 10 people.

Where is IgGenix based?

IgGenix is headquartered in South San Francisco, United States, in the North America region.

How does IgGenix make money?

One revenue line is on record: therapeutic Drug Development and Commercialization.

Who are IgGenix's main competitors?

Emerging players on record are Prota Therapeutics, Mabylon AG, AnaptysBio and Arcutis Biotherapeutics. Direct peers are Alladapt Immunotherapeutics, Allergy Therapeutics, DBV Technologies and Aimmune Therapeutics. Broad incumbents are Sanofi and Regeneron Pharmaceuticals.

Does IgGenix have an API?

No public API is recorded for IgGenix.

What industry is IgGenix in?

IgGenix's product category is Allergy Biologics / Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIgGenix Presents Groundbreaking Research Using its SEQ SIFTER™ Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual MeetingIgGenix announced preclinical data for IGNX001, an IgG4 monoclonal antibody therapeutic candidate for peanut allergy, which demonstrated the ability to prevent severe anaphylactic responses in mouse models. The company also presented findings on using its proprietary SEQ SIFTER™ platform antibodies for allergen quantification testing at the 2024 AAAAI Annual Meeting. These developments support IgGenix's plan to advance IGNX001 into clinical trials later in the year.Pulse 2.0IgGenix Raises $40 Million To Address Allergic DiseasesIgGenix raised $40 million in Series B funding led by Alexandria Venture Investments, with Eli Lilly joining as a new investor. The proceeds will advance its lead peanut allergy program to Phase 1 clinical trials and expand its discovery platform to other IgE-mediated diseases.dlvr.itIgGenix Raises $40 Million To Address Allergic DiseasesIgGenix has secured $40 million in Series B funding to advance its lead peanut allergy program into Phase 1 human clinical trials. The round was led by Alexandria Venture Investments and includes participation from new investor Eli Lilly and Company, alongside existing backers Khosla Ventures and Sean Parker.FinSMEsIgGenix Holds First Close of $40M Series B FinancingIgGenix has secured the first close of a $40 million Series B funding round led by Alexandria Venture Investments, with participation from Eli Lilly and Company. The company plans to utilize these funds to advance its lead program into Phase 1 human clinical trials for severe allergies and expand its discovery platform.Venture Capital Access OnlineIgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut AllergyIgGenix announced the first close of a $40 million Series B financing round to advance its lead antibody program for peanut allergy into Phase 1 clinical trials. The investment was led by Alexandria Venture Investments and includes new investor Eli Lilly and Company, alongside existing backers such as Khosla Ventures. Joel S. Marcus from Alexandria Real Estate Equities has joined the IgGenix Board of Directors to support this development.IggenixIgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy – IgGenixIgGenix announced the first close of a $40 million Series B financing round to advance its lead antibody program for peanut allergy into Phase 1 human clinical trials. The funding was led by Alexandria Venture Investments and included new investor Eli Lilly and Company, alongside existing backers Khosla Ventures and Sean Parker. Joel S. Marcus joined the IgGenix Board of Directors as part of the transaction, with proceeds designated to expand the company's discovery platform beyond allergy treatments.BioSpaceIMIDomics, IgGenix and neuro42 Close Series A Rounds Worth MillionsThree companies announced the closing of Series A financing: IMIDomics raised $16.5 million led by DNS Capital, IgGenix raised $25 million led by Khosla Ventures and Mattias Westman, and neuro42 raised $6.5 million led by Zepp Health. IMIDomics targets immune-mediated diseases including lupus and Crohn's, IgGenix focuses on allergies, and neuro42 advances MRI and robotics for brain injury diagnosis.IggenixIgGenix Announces $25M in Series A1 Funding – IgGenixIgGenix announced the closing of a $25 million oversubscribed Series A1 funding round co-led by Khosla Ventures and Prosperity Capital Management, with participation from new investors including Alexandria Venture Investments. The company intends to use the capital to expand its discovery platform for allergic diseases and accelerate its lead program into preclinical development. This financing supports IgGenix's efforts to develop precision-targeted therapeutics for food allergies, which impact approximately 32 million Americans.BioWorldTime sensitive? Allergy overdue for something new, Iggenix bags $10M series AIggenix, a South San Francisco-based company, raised $10 million in a series A round to fund work on food allergies. CEO Bruce Hironaka said the company is at the front of the wave, noting allergy companies have not fully leveraged biotech developments over the past 20-30 years.